Company Overview - China Oilfield Services Limited (COSL) is a major integrated oilfield service provider globally, offering services across all stages of offshore oil and gas exploration, development, and production [1] - COSL's business is divided into four main categories: geophysical exploration services, drilling services, oilfield technical services, and marine services [1] Stock Performance - On August 12, the Shanghai Composite Index rose by 0.5%, closing at 3665.92 points, while the Hang Seng Index increased by 0.25%, closing at 24969.68 points [1] - COSL's A-shares closed at 14.01 yuan, with an increase of 0.79%, while its H-shares closed at 7.2 Hong Kong dollars, up by 1.84% [1] A/H Share Premium - COSL's A/H share premium reached 112.43%, ranking it 22nd among A/H shares in terms of premium rate [1][2]

Core Viewpoint - The article highlights the performance of the Shanghai Composite Index and the Hang Seng Index on August 11, along with the premium of China Merchants Energy Transportation Co., Ltd. (中远海能) in the A/H share market, emphasizing its position in the energy transportation sector and its operational capabilities [1]. Company Overview - China Merchants Energy Transportation Co., Ltd. was established on June 6, 2016, in Shanghai and is a subsidiary of China Ocean Shipping Group Co., Ltd. [1] - The company specializes in the storage and transportation of oil products, liquefied natural gas (LNG), liquefied petroleum gas, and chemicals, resulting from the merger of the energy transportation segments of China Ocean Shipping and China Shipping [1]. - It aims to become a comprehensive energy transportation solution provider, serving over 200 domestic and international clients across more than 300 global ports [1]. Operational Highlights - The company focuses on two core businesses: tanker transportation and LNG transportation, leveraging years of experience and a strong brand reputation [1]. - It possesses the world's largest tanker fleet capacity, covering all mainstream tanker types, making it the most comprehensive shipping company in terms of vessel types in the global tanker fleet [1]. Market Performance - On August 11, the A-shares of China Merchants Energy closed at 10.17 yuan, down 0.49%, while the H-shares closed at 6.79 HKD, up 0.44% [1]. - The A/H premium for China Merchants Energy reached 63.71%, ranking it 57th among A/H shares, indicating that H-shares are relatively cheaper compared to A-shares [1].

Group 1 - The Shanghai Composite Index rose by 0.34% to close at 3647.55 points, while the Hang Seng Index increased by 0.19% to 24906.81 points [1] - China Oilfield Services Limited (COSL) has an AH premium of 114.89%, ranking 21st among AH shares [1] - COSL's A-shares closed at 13.9 yuan, down 0.79%, and H-shares closed at 7.07 HKD, down 0.28% [1] Group 2 - COSL is a major integrated oilfield service provider globally, offering services across all stages of offshore oil and gas exploration, development, and production [1] - The company's business is divided into four main categories: geophysical exploration services, drilling services, oilfield technical services, and marine services [1] - COSL was publicly listed on the Hong Kong Stock Exchange on November 20, 2002, and has been trading in the U.S. OTC market since March 26, 2004, and on the Shanghai Stock Exchange since September 28, 2007 [1]

Summary of Key Points from the Conference Call Industry Overview - The conference call focuses on the **pharmaceutical and medical device industry** in China, particularly the performance and outlook of various companies within this sector [1][2][3]. Core Insights and Arguments - **Medical Device Sector Growth**: The medical device sector is expected to achieve positive growth in the second half of the year, following significant inventory reduction in the first half, leading to a low base effect. Companies like **Mindray Medical** and **United Imaging** are recommended for investment [1][2]. - **International Market Potential**: The domestic market shows steady growth, but overseas markets, particularly in Europe, Asia, Africa, and Latin America, present significant opportunities. Companies such as **Mindray**, **New Industry Bio**, **Nanwei Software**, and **Newmed** are highlighted for their overseas business expansion, expected to show results starting in 2026 [1][5]. - **Traditional Chinese Medicine (TCM)**: The TCM sector is anticipated to improve in Q3 due to low base effects, reduced inventory, and cost improvements, with companies like **Jichuan Pharmaceutical**, **Kweichow Moutai**, and **Shenwei Pharmaceutical** being of interest [1][6]. - **Biopharmaceuticals**: **Ganli Pharmaceutical** is noted for its strong performance in the insulin market, with high likelihood of completing stock incentives. The competitive landscape for insulin weekly formulations is favorable, and companies like **Anke Bio** and **Changchun High-tech** are also recommended [1][6]. - **Innovation in Drug Development**: There is a diversification in funding sources for innovative drug research and development, with a positive trend in both primary market financing and the establishment of industrial funds. The IPO wave for innovative drugs in Hong Kong is expected to surpass the previous cycle, aided by the loosening of listing regulations for unprofitable companies in A-shares [1][8][9]. Additional Important Insights - **Pricing Trends**: The medical device industry has seen a stabilization in pricing, with most products already undergoing centralized procurement. Future price declines are not expected, and the overall pricing environment is becoming more stable [3][4]. - **BD (Business Development) Trends**: The BD upfront payments have become a significant source of funding for R&D in innovative drugs, enhancing companies' willingness to invest in research. The trend indicates a gradual improvement in R&D investment in China [10]. - **Policy Impact**: Recent domestic policies have been favorable for the innovative drug sector, with expectations for more supportive measures to be introduced. The ongoing negotiations for medical insurance in the second half of the year may further reflect this support [12]. - **International Recognition**: Chinese companies are gaining international recognition for their R&D capabilities, leading to substantial BD transactions in areas like ADC and GLP-1 weight loss drugs, indicating a pivotal moment for Chinese innovation on the global stage [13]. - **Performance of Innovative Companies**: Companies like **BeiGene** and **Innovent Biologics** have shown positive earnings trends, with significant upcoming academic conferences expected to provide critical data supporting future BD transactions [14]. Valuation and Market Dynamics - **AH Premium Trends**: The premium for A-shares over H-shares has been narrowing, with leading companies like **Hengrui Medicine** and **WuXi AppTec** showing signs of premium recovery. As of August 1, 2025, Hengrui's AH premium was -10.37%, while WuXi's was 0.40% [15][17]. - **Future Valuation Predictions**: The Hong Kong pharmaceutical sector is still in a valuation recovery phase, with expectations for the AH premium to continue narrowing as Chinese innovative drug companies expand their international presence [19].

龙源电力AH溢价达157.64%，位居AH股溢价率第八位。当日收盘，龙源电力A股报16.54元，涨幅 0.18%，H股报7.02港元，上涨1.01%。 资料显示，龙源电力集团股份有限公司成立于1993年,当时隶属国家能源部,后历经电力部、国家电力公 司、中国国电集团公司,现隶属于国家能源集团。2009年,在香港主板成功上市,被誉为"中国新能源第一 股"。2022年正式在A股上市,成为国内首单H股新能源发电央企回归A股、首单五大发电集团新能源企业 登陆A股资本市场、首单同步实施换股吸收合并、资产出售和资产购买项目。龙源电力是中国最早开发 风电的专业化公司,率先开拓了我国海上、低风速、高海拔等风电领域,率先实现我国风电"走出去",不断 引领行业发展和技术进步。自2015年以来,持续保持世界第一大风电运营商地位。 *注：AH股是指同时在A股和港股上市的公司，溢价（A/H）越大，说明H股相比A股越便宜。 本文源自：金融界 作者：行情君 8月7日，上证指数涨0.16%，收报3639.67点，恒生指数涨0.69%，收报25081.63点。 ...

Group 1 - The Shanghai Composite Index rose by 0.16% to close at 3639.67 points, while the Hang Seng Index increased by 0.69% to 25081.63 points [1] - China Merchants Industry Holdings Co., Ltd. (the "Company") has an A/H premium of 132.6%, ranking 11th among A/H shares [1] - The Company is a subsidiary of China Ocean Shipping Group Co., Ltd. and specializes in shipping logistics and financial operations [1] Group 2 - The Company was established in 1997 and is headquartered in Shanghai, listed on both Hong Kong and Shanghai stock exchanges [1] - The Company focuses on container manufacturing, leasing, and shipping leasing, supported by investment management for integrated development [1] - The container manufacturing business has an annual production capacity of over 1.4 million TEUs, ranking second globally, serving major shipping lines and leasing companies [1]

Group 1 - The Shanghai Composite Index rose by 0.45%, closing at 3633.99 points, while the Hang Seng Index increased by 0.03%, closing at 24910.63 points [1] - China Shipbuilding Defense's A-H share premium reached 87.7%, ranking 38th among A-H share premium rates [1] - At the close, China Shipbuilding Defense's A-shares were priced at 30.6 yuan, with a gain of 7.41%, and H-shares were priced at 17.8 HKD, up by 7.75% [1] Group 2 - China Shipbuilding Defense Equipment Co., Ltd. is a major shipbuilding enterprise under China Shipbuilding Group, originally established as Guangzhou Shipyard International Co., Ltd. [1] - The company was listed in Shanghai and Hong Kong in 1993, becoming the first A+H share listed shipbuilding enterprise in China [1] - To promote industry consolidation and enhance competitiveness, China Shipbuilding Defense acquired several companies in 2014 and 2015, integrating quality shipbuilding assets in South China [1] - The company aims to become a leading enterprise in the global marine and heavy equipment market, focusing on technology and service excellence [1]

Core Viewpoint - The article highlights the performance of the stock market on August 6, with a focus on the significant price movements of CanSino Biologics, which has a notable A/H share premium and is recognized as a leading high-tech biopharmaceutical company in China [1][3]. Group 1: Market Performance - On August 6, the Shanghai Composite Index rose by 0.45%, closing at 3633.99 points, while the Hang Seng Index increased by 0.03%, closing at 24910.63 points [1]. - CanSino's A-shares closed at 88.48 yuan, reflecting a 6.13% increase, while its H-shares closed at 52.05 HKD, showing a 9.21% rise [1]. Group 2: Company Overview - CanSino Biologics was established in 2009 in China, focusing on providing solutions for the prevention and treatment of infectious diseases globally [1]. - The company specializes in the research, production, and commercialization of innovative, high-quality, and accessible human vaccines, positioning itself as a leading high-tech biopharmaceutical enterprise [1]. - CanSino's mission is to provide innovative, high-quality, and accessible vaccines globally, aiming for the vision of "Innovation without end, a world without epidemics" [1]. - The company is listed on both the Hong Kong Stock Exchange (H-shares, stock code 6185.HK) and the Shanghai Stock Exchange's STAR Market (A-shares, stock code 688185), being the first "A+H" vaccine stock since the launch of the STAR Market [1].

Core Viewpoint - The article highlights the performance of the Shanghai Composite Index and the Hang Seng Index on August 6, along with the premium of New Tian Green Energy's A-shares over H-shares, indicating a significant investment opportunity in the renewable energy sector [1]. Company Overview - New Tian Green Energy Co., Ltd. was established on February 9, 2010, by Hebei Construction Investment and Construction Investment Water Affairs [1]. - The company is primarily engaged in the development and utilization of renewable and clean energy, with operations in wind power, photovoltaic, and natural gas sectors [1]. - New Tian Green Energy has wind and photovoltaic projects across various regions in China, including Hebei, Shanxi, Xinjiang, Shandong, Yunnan, and Inner Mongolia [1]. Market Performance - On August 6, New Tian Green Energy's A-shares closed at 7.75 yuan, with an increase of 0.65%, while its H-shares closed at 4.24 Hong Kong dollars, up by 0.24% [1]. - The A/H premium for New Tian Green Energy reached 99.57%, ranking it 32nd among AH shares, suggesting that H-shares are relatively cheaper compared to A-shares [1].

Core Viewpoint - The article highlights the performance of the Shanghai Composite Index and the Hang Seng Index on August 6, along with the premium of China Railway Signal & Communication Corporation (China Tonghao) in the A/H share market, indicating its position as a leading provider in the rail transit control system industry [1][2]. Company Overview - China Railway Signal & Communication Corporation, referred to as China Tonghao, is a large central enterprise directly supervised by the State-owned Assets Supervision and Administration Commission (SASAC) [1]. - The company specializes in rail transit control technology and is recognized as a global leader in providing rail transit control systems [1]. - China Tonghao has a complete industrial chain that includes investment and financing, design and research, system integration, equipment manufacturing, engineering services, and operation maintenance [1]. - The company is responsible for the formulation of equipment standards, technical standards, and product standards for rail transit control systems in China [1]. Financial Performance - China Tonghao has achieved an A-grade in operational performance assessments for four consecutive years [1]. - The company successfully listed on the Hong Kong Stock Exchange in 2015 and became the first central enterprise and the first A+H share company to be listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board in 2019 [1].